Will a majority government owned company introduce a new GLP-1 drug before 2040?
RegülasyonOne-OffÇinAvrupa13yManifold MarketsKYC yokDoğrulanmış sonuçlanma verisiİyi kalibreGüncel topluluk tahminiHayır 84.1%
Tahminciler
2
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
1 saat önce güncellendi
Gecikmeli25 Oca 25 21:23 UTC31 Ara 39 22:59 UTC
Trendler
Kurallar
Background GLP-1 (Glucagon-like peptide-1) drugs are currently one of the fastest-growing segments in the pharmaceutical industry, primarily used for treating type 2 diabetes and obesity.
- The market is dominated by private companies like Novo Nordisk and Eli Lilly.
- Many sources predict a very significant impact of cost of those drugs on public health systems, which could potentially be solved by a Manhattan Project-like development effort to create a government-owned alternative.
- Resolution Criteria This market will resolve YES if:
- A company that is >50% owned by any national government receives regulatory approval for a new GLP-1 drug in at least two major markets (US, EU, UK, Japan, China) before January 1, 2040
- The drug must be a novel GLP-1 receptor agonist, not a generic version or biosimilar of an existing drug
